全文获取类型
收费全文 | 84440篇 |
免费 | 7507篇 |
国内免费 | 2635篇 |
专业分类
耳鼻咽喉 | 683篇 |
儿科学 | 2189篇 |
妇产科学 | 693篇 |
基础医学 | 5671篇 |
口腔科学 | 561篇 |
临床医学 | 12723篇 |
内科学 | 14052篇 |
皮肤病学 | 641篇 |
神经病学 | 4569篇 |
特种医学 | 3723篇 |
外国民族医学 | 2篇 |
外科学 | 12080篇 |
综合类 | 15176篇 |
现状与发展 | 3篇 |
预防医学 | 5621篇 |
眼科学 | 972篇 |
药学 | 8115篇 |
112篇 | |
中国医学 | 4796篇 |
肿瘤学 | 2200篇 |
出版年
2024年 | 317篇 |
2023年 | 1327篇 |
2022年 | 2824篇 |
2021年 | 3956篇 |
2020年 | 3862篇 |
2019年 | 3124篇 |
2018年 | 2960篇 |
2017年 | 3353篇 |
2016年 | 3324篇 |
2015年 | 2998篇 |
2014年 | 5704篇 |
2013年 | 5626篇 |
2012年 | 4794篇 |
2011年 | 4955篇 |
2010年 | 4102篇 |
2009年 | 3956篇 |
2008年 | 4051篇 |
2007年 | 4232篇 |
2006年 | 3733篇 |
2005年 | 3215篇 |
2004年 | 2591篇 |
2003年 | 2283篇 |
2002年 | 1892篇 |
2001年 | 1804篇 |
2000年 | 1485篇 |
1999年 | 1265篇 |
1998年 | 1096篇 |
1997年 | 1010篇 |
1996年 | 881篇 |
1995年 | 926篇 |
1994年 | 836篇 |
1993年 | 643篇 |
1992年 | 734篇 |
1991年 | 566篇 |
1990年 | 492篇 |
1989年 | 426篇 |
1988年 | 457篇 |
1987年 | 381篇 |
1986年 | 295篇 |
1985年 | 300篇 |
1984年 | 295篇 |
1983年 | 174篇 |
1982年 | 242篇 |
1981年 | 174篇 |
1980年 | 167篇 |
1979年 | 153篇 |
1978年 | 146篇 |
1977年 | 96篇 |
1976年 | 101篇 |
1975年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
891.
Robert Pearson John Asher Andrew Jackson Patrick B. Mark Vlad Shumeyko Marc J. Clancy 《American journal of transplantation》2021,21(3):1317-1321
The role of ex vivo normothermic perfusion (EVNP) in both organ viability assessment and reconditioning is increasingly being demonstrated. We report the use of this emerging technology to facilitate the transplantation of a pair of donor kidneys with severe acute kidney injury (AKI) secondary to rhabdomyolysis. Donor creatinine was 10.18 mg/dl with protein (30 mg/dl) present in urinalysis. Both kidneys were declined by all other transplantation units and subsequently accepted by our unit. The first kidney was perfused with red cell-based perfusate at 37°C for 75 min, mean renal blood flow was 110 ml/min/100 g and produced 85 ml of urine. Having demonstrated favorable macroscopic appearance and urine output, the kidney was transplanted into a 61-year-old peritoneal dialysis dependent without complication. Given the reassuring information from the first kidney provided by EVNP, the second kidney was not perfused with EVNP and was directly implanted to a 64-year-old patient. The first kidney achieved primary function and the second functioned well after delayed graft function. Recipient eGFR have stabilized at 88.5 and 55.3, respectively (ml/min/1.73 m2), at 2 months posttransplant. 相似文献
892.
Tom D. Blydt-Hansen Atul Sharma Ian W. Gibson Chris Wiebe Ajay P. Sharma Valerie Langlois Chia W. Teoh David Rush Peter Nickerson David Wishart Julie Ho 《American journal of transplantation》2021,21(4):1545-1555
Individualized posttransplant immunosuppression is hampered by suboptimal monitoring strategies. To validate the utility of urinary CXCL10/Cr immune monitoring in children, we conducted a multicenter prospective observational study in children <21 years with serial and biopsy-associated urine samples (n = 97). Biopsies (n = 240) were categorized as normal (NOR), rejection (>i1t1; REJ), indeterminate (IND), BKV infection, and leukocyturia (LEU). An independent pediatric cohort of 180 urines was used for external validation. Ninety-seven patients aged 11.4 ± 5.5 years showed elevated urinary CXCL10/Cr in REJ (3.1, IQR 1.1, 16.4; P < .001) and BKV nephropathy (median = 5.6, IQR 1.3, 26.9; P < .001) vs. NOR (0.8, IQR 0.4, 1.5). The AUC for REJ vs. NOR was 0.76 (95% CI 0.66–0.86). Low (0.63) and high (4.08) CXCL10/Cr levels defined high sensitivity and specificity thresholds, respectively; validated against an independent sample set (AUC = 0.76, 95% CI 0.66–0.86). Serial urines anticipated REJ up to 4 weeks prior to biopsy and declined within 1 month following treatment. Elevated mean CXCL10/Cr was correlated with first-year eGFR decline (ρ = −0.37, P ≤ .001), particularly when persistently exceeding ≥4.08 (ratio = 0.81; P < .04). Useful thresholds for urinary CXCL10/Cr levels reproducibly define the risk of rejection, immune quiescence, and decline in allograft function for use in real-time clinical monitoring in children. 相似文献
893.
Christina D. Mejia Adam M. Frank Pooja Singh Anju Yadav 《American journal of transplantation》2021,21(3):1322-1325
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies against inhibitory receptors on T cells resulting in anticancer activity. In kidney transplant (KT) recipients, ICPI use has been associated with acute allograft rejection. In failed allografts, however, the effects of ICPIs are unknown. We present a case of a 66-year-old man with a history of diabetes, renal cell cancer, left native nephrectomy, and end-stage kidney disease. He received a deceased donor KT which failed after 6 years due to biopsy-proven recurrent diabetic nephrosclerosis. He was started on hemodialysis and his immunosuppression was gradually weaned off. A year later, he was diagnosed with renal cell cancer in his right native kidney requiring nephrectomy. He later developed metastasis and was started on combination ICPIs. He developed hematuria, allograft pain, and malaise consistent with graft intolerance syndrome 28 days after starting ICPIs. Urine culture and cystoscopy were normal. A computed tomography scan of his abdomen revealed an enlarged allograft with patchy enhancement. After a multidisciplinary discussion, he underwent transplant nephrectomy. Histopathology showed chronic active T cell–mediated rejection. As ICPI use becomes prevalent, practitioners need to be aware of its potential complications among KT recipients both with functioning and failed allografts. 相似文献
894.
Hanno Niess Nikolaus Börner Maximilian Muenchhoff Elham Khatamzas Manfred Stangl Alex Graf Philipp Girl Enrico Georgi Dionysios Koliogiannis Gerald Denk Michael Irlbeck Jens Werner Markus Guba 《American journal of transplantation》2021,21(4):1629-1632
To date, little is known about the duration and effectiveness of immunity as well as possible adverse late effects after an infection with SARS-CoV-2. Thus it is unclear, when and if liver transplantation can be safely offered to patients who suffered from COVID-19. Here, we report on a successful liver transplantation shortly after convalescence from COVID-19 with subsequent partial seroreversion as well as recurrence and prolonged shedding of viral RNA. 相似文献
895.
Jignesh K. Patel Guillaume Coutance Alexandre Loupy Deanna Dilibero Michele Hamilton Michelle Kittleson Evan Kransdorf Babak Azarbal Osamu Seguchi Xiaohai Zhang David Chang Dael Geft Lawrence Czer Shaida Varnous Jon A. Kobashigawa 《American journal of transplantation》2021,21(7):2479-2488
Allosensitization represents a major barrier to heart transplantation (HTx). We assessed the efficacy and safety of complement inhibition at transplant in highly sensitized heart transplant recipients. We performed a single-center, single-arm, open-label trial (NCT02013037). Patients with panel reactive antibodies (PRA) ≥70% and pre–formed donor-specific antibodies (DSA) were eligible. In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant. The primary composite endpoint was antibody-mediated rejection (AMR) ≥pAMR2 and/or left ventricular dysfunction during the first year. Secondary endpoints included hemodynamic compromise, allograft rejection, and patient survival. Twenty patients were included. Median cPRA and mean fluorescence intensity of immunodominant DSA were 95% (90%–97%) and 6250 (5000–10 000), respectively. Retrospective B cell and T cell flow crossmatches were positive in 14 and 11 patients, respectively. The primary endpoint occurred in four patients (20%). Survival at 1 year was 90% with no deaths resulting from AMR. In a prespecified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR = 0.36, 95% CI = 0.14–0.95, p = .032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk. ClinincalTrials.gov, NCT02013037. 相似文献
896.
Benedict L. Phillips Maria Ibrahim George H. B. Greenhall Lisa Mumford Anthony Dorling Chris J. Callaghan 《American journal of transplantation》2021,21(10):3346-3355
Kidneys from donation after circulatory death (DCD) donors are utilized variably worldwide, in part due to high rates of delayed graft function (DGF) and putative associations with adverse longer-term outcomes. We aimed to determine whether the presence of DGF and its duration were associated with poor longer-term outcomes after kidney transplantation from DCD donors. Using the UK transplant registry, we identified 4714 kidney-only transplants from controlled DCD donors to adult recipients between 2006 and 2016; 2832 recipients (60·1%) had immediate graft function and 1882 (39·9%) had DGF. Of the 1847 recipients with DGF duration recorded, 926 (50·1%) had DGF < 7 days, 576 (31·2%) had DGF 7–14 days, and 345 (18·7%) had DGF >14 days. After risk adjustment, the presence of DGF was not associated with inferior long-term graft or patient survivals. However, DGF duration of >14 days was associated with an increased risk of death-censored graft failure (hazard ratio 1·7, p = ·001) and recipient death (hazard ratio 1·8, p < ·001) compared to grafts with immediate function. This study suggests that shorter periods of DGF have no adverse influence on graft or patient survival after DCD donor kidney transplantation and that DGF >14 days is a novel early biomarker for significantly worse longer-term outcomes. 相似文献
897.
John M. Søfteland Gustav Friman Bengt von Zur-Mühlen Bo-Göran Ericzon Carin Wallquist Kristjan Karason Vanda Friman Jan Ekelund Marie Felldin Jesper Magnusson Ida Haugen Löfman Andreas Schult Emily de Coursey Susannah Leach Hanna Jacobsson Jan-Åke Liljeqvist Ali R. Biglarnia Per Lindnér Mihai Oltean 《American journal of transplantation》2021,21(8):2762-2773
Solid organ transplant (SOT) recipients run a high risk for adverse outcomes from COVID-19, with reported mortality around 19%. We retrospectively reviewed all known Swedish SOT recipients with RT-PCR confirmed COVID-19 between March 1 and November 20, 2020 and analyzed patient characteristics, management, and outcome. We identified 230 patients with a median age of 54.0 years (13.2), who were predominantly male (64%). Most patients were hospitalized (64%), but 36% remained outpatients. Age >50 and male sex were among predictors of transition from outpatient to inpatient status. National early warning Score 2 (NEWS2) at presentation was higher in non-survivors. Thirty-day all-cause mortality was 9.6% (15.0% for inpatients), increased with age and BMI, and was higher in men. Renal function decreased during COVID-19 but recovered in most patients. SARS-CoV-2 antibodies were identified in 78% of patients at 1–2 months post-infection. Nucleocapsid-specific antibodies decreased to 38% after 6–7 months, while spike-specific antibody responses were more durable. Seroprevalence in 559 asymptomatic patients was 1.4%. Many patients can be managed on an outpatient basis aided by risk stratification with age, sex, and NEWS2 score. Factors associated with adverse outcomes include older age, male sex, greater BMI, and a higher NEWS2 score. 相似文献
898.
899.
900.